Global Health

Global Health ROE

The Return on Equity (ROE) of Global Health (MEDANTA.NS) as of Nov 7, 2026 is 14.05 %. In the previous year, Return on Equity (ROE) was 14.22 % — a change of -1.20% (lower).

ROE

14.05 %

YoY

-1.20%

Last updated:

In 2026, Global Health's return on equity (ROE) was 14.05 %, a -1.20% increase from the 14.22 % ROE in the previous year.

The Global Health ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
3.96 INR
Jan 1, 2020
2.69 INR
Jan 1, 2021
2.08 INR
Jan 1, 2022
12.14 INR
Jan 1, 2023
13.43 INR
Jan 1, 2024
16.46 INR
Jan 1, 2025
14.22 INR
Jan 1, 2026
14.05 INR
The Global Health ROE history
YEARROEYoY
14.05 %-1.20%
14.22 %-13.62%
16.46 %+22.55%
13.43 %+10.61%
12.14 %+482.64%
2.08 %-22.59%
2.69 %-32.03%
3.96 %+46.64%
2.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Global Health Stock analysis

What does Global Health do? Global Health Ltd. provides healthcare, pathology, and medical services through its Medanta brand, operating five hospitals in Delhi, Gurugram, Indore, Ranchi, Patna, and Lucknow, alongside six Mediclinic diagnostic laboratories. The company generates revenue by delivering treatments for conditions such as coronary artery disease, head and neck cancer, acute myeloid leukemia, and chronic kidney disease, alongside specialized services in cardiac surgery, nephrology, urology, and interventional cardiology. Its offerings include medicine delivery, lab tests & diagnostics, homecare, and telemedicine, targeting patients seeking advanced medical care across multiple specialties. Medanta serves urban and semi-urban segments in India, focusing on high-demand treatments and comprehensive healthcare solutions. The company monetizes through direct patient services at its hospitals and diagnostic centers, with revenue derived from procedures, consultations, and diagnostic tests. Treatments for chronic conditions like diabetes, hypertension, and bronchial asthma, as well as acute cases such as cerebral stroke and sepsis, form a significant portion of its service portfolio. Patients utilize Medanta’s telemedicine and homecare services for convenience, while its diagnostic labs provide lab tests & diagnostics to both in-person and remote clients. Revenue streams are driven by high-volume treatments and specialized medical expertise across its network of facilities. Medanta’s service mix includes cardiology, oncology, neurology, and orthopedics, with a focus on conditions like Parkinson’s disease, prostate cancer, and rheumatoid arthritis. The company’s revenue model relies on comprehensive care packages, including hospital stays, outpatient visits, and follow-up services. Its facilities in Delhi, Gurugram, and other cities cater to both private and government-affiliated patients, though the business description does not specify government contracts. The company’s diagnostic laboratories and telemedicine services expand its reach, enabling revenue from multiple touchpoints within the healthcare ecosystem. Global Health is one of the most popular companies on Eulerpool.

ROE Details

Decoding Global Health's Return on Equity (ROE)

Global Health's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Global Health's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Global Health's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Global Health’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Global Health stock

Return on Equity (ROE) of Global Health is 14.05 % in 2026.

Return on Equity (ROE) of Global Health changed from 14.22 % to 14.05 %, representing a -1.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Global Health since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Global Health with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Global Health

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Global Health